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Abstract
Background: The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast
cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects
of this combined target modulation. We conducted a phase 0/I clinical trial in an adjuvant setting, with the
goal of obtaining pharmacodynamic proof of the effects of combined aromatase and FGFR1 inhibition and to
establish the RP2D for nintedanib combined with letrozole.
Patients and methods: Women with early-stage luminal breast cancer were eligible for enrollment in the
study. Dose level 1 was nintedanib (150 mg/bid) plus letrozole (2.5 mg/day) administered for a single 28-day
cycle (DLT assessment period), followed by a classic 3 + 3 schedule. FGF23 and 17-B-estradiol levels were
determined on days 0 and 15; pharmacokinetic parameters were assessed on days 1 and 28. Patients were
allowed to continue treatment for 6 cycles. The primary study endpoint was a demonstration of FGFR1 modulation
(defined as a 25% increase in the plasma FGF23 level).
Results: A total of 19 patients were enrolled in the study (10 in the expansion cohort following dose escalation). At the
RP2D (nintedanib 200mg/bid plus letrozole 2.5 mg/day), we observed a 55% mean increase in the plasma FGF23 level,
and 81.2% of the patients had no detectable level of 17-B-estradiol in their plasma (87.5% of the patients treated with
letrozole alone). Nintedanib and letrozole displayed a pharmacokinetic interaction that led to three- and
twofold increases in their respective plasma concentrations. Most G3 toxic events (5 out of 6: 2 diarrhea and
3 hypertransaminasemia) occurred subsequent to the DLT assessment period.
Conclusion: Combined treatment with nintedanib (200mg/bid) plus letrozole (2.5 mg/day) effectively suppressed
FGFR1 and aromatase activity, and these respective doses can be used as starting doses in any subsequent trials.
However, drug-drug interactions may produce tolerability issues when these drugs are co-administered for an
extended time period (e.g., 6 months). Patients enrolled in future trials with these drugs should be carefully monitored
for their FGF23 levels and signs of toxicity, and those findings should guide individualized treatment decisions.
Trial registration: This trial was registered at www.clinicaltrials.gov under reg. # NCT02619162, on December 2, 2015.
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Background
Several biological factors are known to modulate the sen-
sitivity of hormone receptor-positive advanced breast can-
cer to hormonal therapy [1], which is the cornerstone for
clinical management of this disease. One of these factors
is the amplification of fibroblast growth factor receptor 1
(FGFR1) [2]. Retrospective studies suggest that ~ 10% of
breast cancer patients harbor this amplification [2, 3]. Al-
though FGFR1 amplification can occur in triple-negative
breast cancer, it most commonly occurs in hormone
receptor-positive breast cancer [2–4]. FGFR1 amplifica-
tion has been linked to ligand-dependent and ligand-inde-
pendent increases in MAPK and Pi3K activation and
signaling [2, 5], tumor progression [6], resistance to hor-
monal inhibitors [6, 7], early distant disease relapse, and
poor patient survival rates, despite standard-of-care treat-
ment of loco-regional disease [3, 4].
Several small molecules that target FGFR receptors have
been developed and can be divided into three main classes
[6]: (1) non-selective and selective tyrosine-kinase inhibi-
tors (TKIs), (2) monoclonal antibodies, (3) FGF ligand
traps. Among these, TKIs are at the most advanced stages
of development, and several of those agents have shown
promising clinical efficacy when used to treat tumors that
harbor activating mutations in at least one of the four
FGF receptors [5, 8, 9]. Nintedanib is a TKI with activity
against the FGFR, VEGFR, and PDGFR families, as well as
other targets [10]. Preclinical pharmacology studies in
tumor models have suggested an antiangiogenic profile
for nintedanib [10–12] and that drug has shown clinical
activity in cases of mesothelioma [13], lung cancer [14],
and breast cancer [15]. Nintedanib is currently ap-
proved for use in combination with docetaxel for
treating advanced lung cancer that has progressed
after first-line chemotherapy. Preclinical studies have
shown that nintedanib exerts an anti-fibrogenic effect
by blocking FGFR1 in fibroblasts [16]. This effect ac-
counts for its clinical activity in treating cases of idio-
pathic pulmonary fibrosis, which is one indication for
which nintedanib was approved on the basis of posi-
tive results in randomized clinical trials [17, 18]. As a
multi-targeted inhibitor, nintedanib has been tested
for its anti-cancer effects mostly as an antiangiogenic
agent; however, its activity as an FGFR1 inhibitor in
oncology remains unexplored.
Non-specific and specific FGFR inhibitors have shown
only moderate levels of toxicity; however, their various
toxic effects become more evident with long-term use [6].
Specific FGFR inhibitors cause hyperphosphatemia, muco-
sitis, hair modification, eye toxicity, osteoarticular toxicity,
and onycholysis, whereas non-specific agents also produce
other side effects such as fatigue, anorexia, gastrointestinal
and liver toxicity, and VEGFR inhibition-related toxicity
[6]. Interestingly, nintedanib has a favorable toxicity
profile when administered alone [19] or in combination
with other agents [20–22].
Selective pan-FGFR inhibitors have been used after the
successful completion of dose-escalation trials in “bas-
ket” clinical trials in a histology-agnostic manner. While
two large trials were recently completed, neither trial
showed encouraging activity: in arm W of the MATCH
trial, the response rate to AZD4547 was low (8%) and
the agent’s activity was greater in tumors with FGFR
gene fusions than in those with FGFR amplifications.
However, the patients with FGFR amplifications showed
better clinical effects (50% disease stabilization rate) than
the patients with FGFR1 SNVs [23]. Another clinical
trial that used Debio1347 in multiple tumor types
yielded similar efficacy results [24]. A significant number
of patients in both trials (32% and 21%) were breast can-
cer patients with FGFR amplifications. One trial that ex-
amined the efficacy of a FGFR1 inhibitor combined with
the multikinase inhibitor dovitinib showed impressive
clinical activity in patients who had advanced hormone
receptor-positive breast cancer with FGFR1 amplifica-
tion [25]. However, strong preclinical data suggests that
the maximum efficacy of that intervention should be ob-
served in when it is administered in combination with
hormonal agents [2, 7]. Thus, developing the combin-
ation of nintedanib plus a hormonal agent as a treat-
ment for FGFR1-amplified hormone receptor-positive
breast cancer would be appealing, once a pharmacody-
namic modulation of FGFR1 at a standard clinical dose
has been demonstrated. Possible clinical settings for
testing such combinations (always in FGFR1-amplified
patients) include an advanced disease setting and in pa-
tients with high-risk early breast cancer in an adjuvant
setting. Prior to considering a large-scale trial in either
setting, we sought to better understand the potential
clinical effects that might be produced by a combin-
ation of nintedanib plus letrozole in patients with hor-
mone receptor-positive breast cancer. Specifically, we
aimed to (1) determine whether nintedanib adminis-
tered in combination with letrozole at the recom-
mended phase-II dose levels (RP2D) would prove the
pharmacodynamic effect of FGFR1 inhibition (i.e., an
increase in plasma FGF23 levels) [26], while maintain-
ing letrozole-induced 17-B-estradiol suppression; (2)
study potential pharmacokinetic interactions between
the two drugs; and (3) assess the short-term and
long-term toxicity of the combination. To that end, we
conducted a phase 0/I clinical trial in hormone
receptor-positive breast cancer patients that had previ-
ously completed loco-regional treatment and were can-
didates for receiving aromatase inhibitors in an
adjuvant setting. Because the patients received the ex-
perimental treatment during their adjuvant stage, no ef-
ficacy endpoints were included in this trial.
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Patients and methods
This was a prospective, open-label, multicenter, single-
arm phase 0/1 investigator-initiated study. The study was
conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice standards. Institutional Review
Board approval was obtained from all the participating
hospitals, and all patients provided their written informed
consent prior to enrollment. The study was registered at
Clinicaltrials.gov (NCT02619162).
Study population
Females ≥ 18 years old were eligible for enrollment if
they had a hormone receptor-positive breast tumor (de-
fined as positivity for the ER and/or PR in > 5% of tumor
cells tested at the local pathology department) > 1 cm in
size that had been adequately treated within less than 6
months prior to registration and were amenable to
receiving the aromatase inhibitor letrozole as a part of
their adjuvant treatment. Patients had to be post-meno-
pausal according to any of the following criteria: (1)
women of any age who had a bilateral oophorectomy
(including radiation castration and confirmed by subse-
quent amenorrhea for > 3 months) and were amenor-
rheic for > 3 months, (2) women that had spontaneous
cessation of menses for ≥ 12 consecutive months, (3)
women that had FSH, LH, and 17-B-estradiol levels in
postmenopausal ranges without an alternative cause. A
minimum of 4 weeks and a maximum of 24 weeks be-
tween the last treatment procedure (chemotherapy and/
or radiation therapy; 6 weeks from major surgery) and
registration were allowed. Patients had to have been tak-
ing letrozole for at least 4 weeks prior to registration.
Other inclusion criteria included the following: an
ECOG performance status of 0–1; adequate liver, renal,
and hematologic function (defined as serum bilirubin <
1.25-fold the upper limit of normal [ULN], AST/ALT <
1.25-fold the ULN, serum creatinine < 1.5-fold the ULN
or creatinine clearance < 50 mL/min, hemoglobin > 10 g/
dL, a platelet count > 100 × 109/L, and a granulocyte
count > 1.5 × 109/L), and LVEF > 50%. Patients who had
not recovered from previous toxicity to a tolerable grade
of ≤ 2, who had bilateral tumors, who had concurrent se-
vere conditions, who were taking anticoagulants, or with
a history of clinically significant bleeding or thrombo-
embolic events within 6 months of study entry were ex-
cluded from the study. A CT scan showing the lack of
metastatic spread was required within 4 weeks prior to
trial registration (plus bone scintigraphy and/or brain
MRI, if indicated).
Study design and procedures
Patients started by taking letrozole at a fixed oral dose of
2.5 mg/day plus nintedanib bid on a continuous sched-
ule. One treatment cycle was defined as 28 consecutive
days of continuous treatment with both agents. Three
dose levels of nintedanib were available for use: 150mg/
bid (level 1), 200 mg/bid (level 2), and 250 mg/bid (level
3). Dose escalation followed a classic 3 + 3 schedule. The
first cycle was the dose-limiting toxicity (DLT) assess-
ment period and was mandatory for all patients. DLT
was defined as the occurrence of drug-related adverse
events during the first treatment cycle; these events in-
cluded grade 4 anemia or thrombocytopenia at any time;
grade 4 neutropenia persisting for ≥ 5 days; grade 3 nau-
sea, diarrhea, or vomiting in spite of maximal supportive
care and prophylaxis; clinically significant grade 3 or
greater non-hematologic toxicity (not including alopecia,
anorexia, or fatigue); and a serum creatinine value ≥
2-fold the baseline value or ≥ 2-fold the ULN if the base-
line value was less than the ULN. The recommended
phase 2 dose (RP2D) was the level at which fewer than
two of a minimum of six patients experienced DLT. An
expansion cohort started at the RP2D after the
dose-escalation part of the study was completed.
Patients being treated at level 1 were allowed one nin-
tedanib dose reduction (to 100mg/bid), whereas patients
at levels 2 and 3 were allowed two 50 mg/bid dose re-
ductions. Patients requiring further nintedanib dose re-
ductions or patients requiring letrozole dose reductions
were removed for the trial. Patients were followed up on
a weekly basis during cycle 1, on a bi-weekly basis dur-
ing cycle two, and every 4 weeks afterwards.
Patients who had completed their first cycle of treat-
ment in either the dose escalation or expansion cohort
portion of the study without experiencing significant
toxicity were allowed to continue their treatment for 5
additional cycles. Patients who completed 6 cycles (and
patients coming off a trial at earlier time points because
of a personal or investigator decision or significant tox-
icity) stopped receiving nintedanib and were given
standard letrozole treatment according to current adju-
vant disease management guidelines. Figure 1 depicts
the basic trial design.
The primary study endpoint was the change in FGF23
levels (pg/mL) from baseline to day + 15. Secondary end-
points were (1) change in 17-B-estradiol levels (pg/mL)
from baseline to day + 15, (2) toxicity graded according
to NCI CTCAE V.4.03, and (3) letrozole and nintedanib
pharmacokinetic parameters and interactions.
Pharmacokinetics and pharmacodynamics
Blood samples (two 5-mL EDTA tubes per time point—
one for each agent’s pharmacokinetic determinations)
were collected on days 1 and 2 and again on days 29
and 30, at 0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 7 h, and
24 h after taking both oral agents, and used to determine
the pharmacokinetic parameters of nintedanib and letro-
zole. For the extraction of letrozole from human plasma,
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10 μL of plasma was added to 200 μL of acetonitrile, and
the mixture was centrifuged. Next, a 50-μL aliquot of
the supernatant was injected into a Thermo UPLC-MS/
MS system. Two species of nintedanib were identified:
BIBF1120-BS (nintedanib) and its active metabolite,
BIBF1202-ZW. The assay comprised a solid phase ex-
traction step in a 96-well plate format followed by quan-
tification by LC-MS/MS using deuterated internal
standards. The samples were analyzed on a Sciex API
5000 LC-MS/MS system. An electrospray ion source (at-
mospheric pressure ionization (API)) was used for
ionization. Measurements were taken in the positive
ionization mode. Separation was accomplished by injec-
tion onto a Phenomenex Luna (C18) 100 Å, 30 × 2.0 mm
(3.0 μm) HPLC column. All of the analytes were well
separated by the column, and the internal standards
co-eluted with their respective analytes. Thermo XCali-
bur and LCQuan software were used to calculate drug
concentrations, and the results were used to perform
pharmacokinetic analyses with the PK Solutions software
package (Summit Research Services). The lower limits of
detection for the pharmacokinetic assays were 1 ng/mL
for letrozole, 0.05 ng/mL for BIBF1120-BS, and 0.1 ng/
mL for BIBF1202-ZW.
One additional blood sample (7-mL BD Vacutainer
CPT Tube) was obtained on day + 1 and again on day +
15 prior to the morning nintedanib dose and used to de-
termine FGF23 levels. Native FGF23 was determined at
the central laboratory by using a FGF23-ELISA Kit from
Millipore according to the manufacturer’s instructions.
Briefly, FGF23 molecules were captured from the sam-
ples in the wells of a microtiter plate that had been
coated with a polyclonal goat anti-human FGF-23 anti-
body. A second biotinylated polyclonal goat anti-human
antibody was added to the captured molecules, followed
by the binding of streptavidin-horseradish peroxidase
conjugate to the immobilized biotinylated antibodies.
The levels of immobilized antibody-enzyme conjugates
were quantified by measuring horseradish peroxidase
activity in the presence of the substrate 3,3′,5,5′-tetra-
methylbenzidine. Enzyme activity was measured spectro-
photometrically as the increase in absorbance at 450–
590 nm after acidification of the formed products. All
samples were assayed in triplicate, and values were
expressed in picograms per milliliter.
17-B-estradiol levels were determined at each of the
following time points: within 7 days after the first dose
of nintedanib (“baseline”), on day 15 of cycle 1, on day 1
Fig. 1 Trial design. Patients completing the treatment for early hormone receptor-positive breast cancer that were eligible for letrozole treatment
and were receiving it for a minimum of 4 weeks were enrolled in the trial. This design allowed testing whether letrozole adjuvant treatment was
actually achieving its therapeutic goal (17-B-estradiol suppression) and whether the concurrent administration of nintedanib exerted any negative
influence on it even in the absence of pharmacokinetic interactions between both drugs. Cycle 1 was mandatory and included pharmacokinetic
profiling and pharmacodynamic endpoints (FGF23 and 17-B-estradiol suppression). Cycles 2 to 6 were included in order to provide the option for
any potential benefit that a long-term administration of a multi-tyrosine-kinase inhibitor could imply in the adjuvant setting, as long as patients
willingly decided to continue treatment and no toxicity was observed. After completing 1 to 6 cycles, patients continued on standard adjuvant
letrozole treatment. And end-of-treatment (EOT) visit was scheduled 28 days after the last nintedanib dose
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of every subsequent cycle, and finally at the
end-of-treatment visit (EOT, 28 days after the last study
dose). Those levels were determined at each study site
with a clinical assay that used blood samples drawn for
the trial procedures. The assay’s lower limit of detection
(LLD) was 5 pg/mL.
Statistical analysis
The sample size needed for the dose-escalation portion
of the study was determined by the requirements for a
classic 3 + 3 design. The sample size for the expansion
cohort portion was determined by estimating the ex-
pected change in FGF23 levels after 14 days of treatment
with nintedanib. When using a power of 80% and an
alpha error of 5%, a minimum of 15 subjects were neces-
sary to observe at least a 25% increase in the median
plasma FGF23 level. Assuming that the nintedanib dose
level would define the RP2D, we needed to recruit a
minimum of six patients, and after including those pa-
tients in the pharmacodynamic analysis, an expansion
cohort of ten patients was sufficient to demonstrate the
primary endpoint.
All patients who received at least one dose of nintedanib
plus letrozole were included in the toxicity and correlation
analysis. The correlation between BIBF1120-BS AUC and
FGF23 blood levels was examined using Pearson’s R2 coef-
ficient. FGF23 and 17-B-estradiol levels were compared by
using non-parametric (Wilcoxon rank) tests that were per-
formed with SPSS V.19 software.
Results
Patient characteristics
From September 2015 to November 2017, 20 patients
were enrolled in the study. There was 1 screening failure
(baseline elevation of transaminases beyond the inclu-
sion criteria limit), for a total number of 19 evaluable pa-
tients. Characteristics of the enrolled patients are shown
in Table 1. All 19 patients were included in the toxicity,
pharmacokinetic, and pharmacodynamic evaluations.
RP2D determination and treatment duration
Three patients were enrolled in the first level of the
study, and no grade 3 or non-tolerable grade 2 toxicities
were observed.
Accrual then proceeded to the second level of the
study. The third patient recruited in level 2 experienced
grade 3 hypertension after 3 weeks of treatment. That
patient was not previously hypertensive and had no his-
tory of taking blood pressure-lowering medications;
therefore, the patient’s hypertension qualified as a DLT.
Three more patients were enrolled in level 2. No further
DLTs were observed among those patients during the
first cycle, but all 3 patients experienced at least 1 grade
1 or 2 event. At that point, after taking into account the
observed DLT and existing toxicity data (particularly
the high incidence of diarrhea) obtained from other
studies that has used long-term administration of nin-
tedanib at 250 mg/bid on a continuous schedule [21,
27–29], the steering committee decided to increase
the number of subjects at that level. Ten more pa-
tients were accrued, and no additional patient experi-
enced a DLT during the DLT assessment period.
However, 5 out of 16 patients required a
dose-reduction at that level during subsequent cycles
because of grade 3 toxicity events that would have
been defined as DLTs if they had occurred during the
first cycle. With the exception of one grade 3 liver
enzyme elevation event and a grade 3 diarrhea event
(which in both patients, persisted despite dose reduc-
tion), the remaining grade 3 events were reversed
after undertaking one level of dose reduction. How-
ever, no further escalation to 250 mg/bid was
attempted. Thus, the RP2D was defined as 2.5 mg of
letrozole combined with nintedanib (200 mg/bid).
All three patients in level 1 decided to continue treat-
ment through the optional phase. Two of those patients
completed 6 months of dosing without a significant toxic
event, whereas the other patient withdrew her consent
after 3 cycles because of prolonged grade 2 asthenia.
Among the patients enrolled in level 2, 4 patients chose
not to continue treatment after the first cycle (1 because
of an investigator’s decision after diagnosing grade 3
high blood pressure; the other 3 patients did not report
any particular reason). One additional patient was not
offered continuation by the investigator. The remaining
11 patients decided to continue through the optional
phase and completed a median number of 6 cycles (2 cy-
cles: 1 patient; 3 cycles: 1 patient; 4 cycles: 3 patients; 6
cycles: 6 patients). The overall median treatment dur-
ation was 112 days (range, 15–175 days).
Pharmacodynamics
The following two pharmacodynamic parameters were
investigated in order to ascertain whether each agent
was exerting its expected effect, despite any pharmacoki-
netic changes induced by concurrent administration: (1)
plasma FGF23 increase on day 15 versus day 1 (second-
ary to FGFR1 inhibition) and (2) the change in
17-B-estradiol level on day 15 versus day 1. Whereas we
expected to observe an increase in plasma FGF23 con-
centrations, we expected that 17-B-estradiol would re-
main below its LLD. Estradiol was also measured during
the last dosing cycle and at the EOT visit.
Figure 2a depicts the average FGF23 plasma concen-
trations of patients in the expansion cohort. There was
an approximate 50% increase in FGG23 levels on day 15
versus day 1 (38.7 pg/mL on day 15 versus 24.9 pg/mL
on day 1; P = 0.021). Figure 2b shows the relationship
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between BIBF1120-BS exposure and blood FGF23 levels.
In general, on day 15, higher BIBF1120-BS AUC values
were found to be correlated with higher FGF23 levels
(R2 = 0.49; P = 0.033).
All but two patients (87.5%) had undetectable
17-B-estradiol levels on day 1 (Fig. 2c). Interestingly, three
(18.7%) and four (25%) patients had 17-B-estradiol levels
above the LLD on day 15, and also during the last cycle,
which is equivalent to 81.2% and 75% of the patients hav-
ing undetectable 17-B-estradiol levels, respectively. All pa-
tients (100%) had undetectable 17-B-estradiol levels 4
weeks after ceasing nintedanib administration (Fig. 2c).
Toxicity
All patients experienced at least one grade 1 toxic event.
No grade 4 toxicity or toxic deaths were registered.
Table 2 lists the toxic events that were registered in at
least 10% of the patients, and those events are catego-
rized by being causally associated with nintedanib or
letrozole. The majority of side effects were grade 1/2.
The grade 3 increase in liver enzymes was transient and
restricted to the first cycle in all cases, with the excep-
tion of one patient who required a nintedanib dose re-
duction, experienced persistent grade 3 toxicity in cycle
4, and decided to withdraw consent. The three grade 3
Table 1 Demographic and baseline clinical characteristics
Characteristic Level N (%)
Age (years; median, range) Level 1 50.6 (50.1–51.5)
Level 2 59.5 (53.4–69.2)
Total 57.5 (50.1–69.2)
ECOG Level 1 0: 3/3 (100%)
Level 2 0: 16/16 (100%)
Total 0: 19/19 (100%)
Tumor size Level 1 T1: 3/3 (100%)
Level 2 T1: 8/16 (50%); T2: 8/16 (50%)
Total T1: 11/19 (58%); T2: 8/19 (42%)
Nodal status Level 1 N0: 2/3 (66.6%); N1: 1/3 (33.3%)
Level 2 N0: 9/16 (56.2%); N1: 6/16 (37.5%); N2: 1/16 (6.2%)
Total N0: 11/19 (57.9%), N1: 7/19 (36.8%); N2: 1/19 (5.3%)
ER and/or PR > 5% Level 1 3/3 (100%)
Level 2 16/16 (100%)
Total 19/19 (100%)
HER2 Level 1 0/3 (0%)
Level 2 0/16 (0%)
Total 0/19 (0%)
Grade Level 1 G1: 3/3 (100%)
Level 2 G1: 9/16 (56%); G2: 6/16 (38%); G3: 1/16 (6%)
Total G1: 12/19 (64%); G2: 6/19 (31%); G3: 1/19 (5%)
Ki67 (average, range) Level 1 9% (3–15%)
Level 2 11.5% (2–43%)
Total 11.1% (2–43%)
Adjuvant/neoadjuvant chemotherapy prior to
study registration
Level 1 0/3 (0%)
Level 2 Anthracyclines plus taxanes: 5/16 (31.3%); taxanes only: 1/16 (6.2%); none: 10/16 (62.5%)
Total Anthracyclines plus taxanes: 5/19 (26.4%); taxanes only: 1/19 (5.3%); none: 13/19 (68.3%)
Letrozole time (days) at study registration
(average, range)*
Level 1 134 (131–140)
Level 2 117 (29–220)*
Total 119 (29–220)*
*The trial allowed patients that had completed their adjuvant treatment and had already started letrozole for a minimum of 4 weeks. Two patients started
letrozole before scheduled adjuvant radiation therapy, and because of this reason, they had been receiving letrozole for 209 and 220 days. However, since they
did not receive other modality of non-standard adjuvant treatment in between, they were allowed to enter the trial despite a maximum pre-established boundary
of 180 days in letrozole prior to study registration
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diarrhea events were successfully managed with ninteda-
nib dose reduction and loperamide in two cases, whereas
the third patient decided to interrupt treatment after the
third cycle. That patient’s diarrhea was resolved at the
end-or-treatment visit. Regarding hypertension, one pa-
tient (dose level 2, expansion cohort) was already taking
two agents for adequate blood pressure control and was
thus classified as grade 3 hypertension. That patient did
not require dose-adjustment or any change of her
anti-hypertensive medications. The other patient with
grade 3 hypertension had not been previously diag-
nosed with hypertension but presented with a systolic
blood pressure of 165 on day 28; the investigator
considered that the patient had completed the study’s
treatment phase and would not obtain additional ben-
efits from continued participation and treatment. That
patient was removed from the study and constituted
the DLT observed among the first three patients re-
cruited in level 2. No grade 3 toxic events were at-
tributed to letrozole.
A B
C
Fig. 2 Pharmacodynamic parameters. a Change of FGF23 plasma concentration from baseline to day + 15 in level 2 patients. Horizontal error
bars: standard error. The average concentration (columns) shifted from 24.9 pg/mL (baseline) to 38.7 pg/mL (d + 15). Each dot represents the
value of a single patient. *P < 0.05 (Wilcoxon). b Dot plot showing the relationship between BIBF1120-BS AUC and FGF23 on day 15 at the
individual patient level. c Change of 17-B-estradiol levels from baseline to day + 15, the first day of the last cycle, and at the EOT visit. Each gray
dot represents one patient with 17-B-estradiol levels below the LLD. Red dots represent the individual 17-B-estradiol levels of those patients that
showed a concentration above the LLD. Regarding the patients below the LLD, although the exact levels might be lower, all of them are plotted
at the level of Y = 5 pg/mL which was our LLD
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No patient required a nintedanib dose reduction in
level 1. In level 2, four patients required one dose reduc-
tion (two because of grade 3 diarrhea [resolved], one be-
cause of prolonged grade 2 asthenia and grade 3
diarrhea [non-resolved], and one because of grade 3
ALT elevation [resolved], and one patient required two
dose reductions [the first time because of grade 3 AST/
ALT elevation and second time because of grade 3 GGT
elevation [non-resolved]]). No patient required a letro-
zole dose reduction. Overall, toxicity was well managed
with supportive measures and reversed after discontinu-
ation of treatment. No severe adverse events were regis-
tered. Other toxicities commonly attributed to
multi-tyrosine-kinase inhibitors such as skin rash or
palmar-plantar erythrodysesthesia were observed in 6.5%
(grade 1) and 0% of the patients, respectively.
Pharmacokinetics
On day 1, all patients had taken letrozole for at least 28
days and had steady-state plasma concentrations. The
introduction of nintedanib induced an increase in the
mean Cmax letrozole plasma concentrations (Fig. 3a)
and mean letrozole AUC values (Table 3) in dose level 2.
In addition, continuous nintedanib administration in-
duced a further increase in both parameters, according
to the values recorded for letrozole pharmacokinetic pa-
rameters on day 29 (Fig. 3a, Table 3).
Conversely, there was no period during the trial when
nintedanib was administered as monotherapy. As ex-
pected, the values for the nintedanib pharmacokinetic
parameters were higher on day 29 than on day 1 and, as
expected, were higher in the level 2 patients compared
to the level 1 patients (Table 3, Figs. 3b and c). The
mean plasma BIBF1120-BS and BIBF1202-ZW concen-
trations were almost twofold higher during their steady
states (day 29) when compared with their plasma con-
centrations on day 1 (level 2; Fig. 3b, c). Whereas this in-
crease in nintedanib concentration seen on day 29
versus day 1 has been previously described [19], the con-
current administration of letrozole led to almost three-
fold increases in AUC and mean plasma concentration.
Discussion
Phase 0 trials have the ability to gather data that can be
used to optimize time and resources during the drug de-
velopment process by allowing go/no-go decisions to be
made in a relatively short time period and at a controlled
cost [30]. In this phase 0/1 trial, in addition to studying
the toxicity and long-term tolerability of the combin-
ation of letrozole plus nintedanib, we sought to deter-
mine whether both drugs were exerting their expected
pharmacodynamic effect, even in the presence of signifi-
cant pharmacokinetic interactions.
In the rapidly evolving field of biomarker-driven disease
segmentation, FGFR1 has been investigated as a potential
driver of several hormone-refractory/resistant clinical con-
ditions that can be included within the overall category of
hormone receptor-positive breast cancer [2–4]. Preclinical
data suggest that the optimal treatment for this disease
cluster would consist of a hormone-blocking agent com-
bined with an FGFR inhibitor [2, 7]. Eventually, registra-
tion trials aimed at improving the disease control rates in
Table 2 Adverse events graded according to NCI CTC AE V.4.03 registered in at least 10% of the patients related to the study drugs
Level 1 Level 2 Total
Grades 1–2 Grade 3 Grade 1–2 Grade 3
Nintedanib-related event
Diarrhea 1/3 (33%) 0/3 (0%) 9/16 (56%) 3/16 (18.8%) 13/19 (68%)
Nausea 2/3 (66.6%) 0/3 (0%) 9/16 (56%) 0/16 (0%) 11/19 (58%)
Vomiting 2/3 (66.6%) 0/3 (0%) 9/16 (56%) 0/16 (0%) 11/19 (58%)
Asthenia 1/3 (33%) 1/3 (33%) 9/16 (56%) 0/16 (0%) 11/19 (58%)
Elevated GGT 0/3 (0%) 0/3 (0%) 4/16 (25%) 4/16 (25%) 8/19 (42%)
Elevated AST 1/3 (33%) 0/3 (0%) 4/16 (25%) 2/16 (12.5%) 7/19 (36.8%)
Elevated ALT 0/3 (0%) 0/3 (0%) 4/16 (25%) 2/16 (12.5%) 6/19 (31.5%)
Hyporexia 0/3 (0%) 0/3 (0%) 3/16 (18.8%) 0/16 (0%) 3/19 (15.8%)
Dysgeusia 1/3 (33%) 0/3 (0%) 2/16 (12.5%) 0/16 (0%) 3/19 (15.8%)
Hypertension 0/3 (0%) 0/3 (0%) 0/16 (0%) 2/16 (12.5%) 2/19 (10.5%)
Headache 1/3 (33%) 0/3 (0%) 1/16 (6.2%) 0/16 (0%) 2/19 (10.5%)
Letrozole-related event
Asthenia 2/3 (66.6%) 0/3 (0%) 8/16 (50%) 0/16 (0%) 10/19 (52.6%)
Arthralgia 1/3 (33%) 0/3 (0%) 7/16 (43.8%) 0/16 (0%) 8/19 (42%)
Hot flushes 1/3 (33%) 0/3 (0%) 6/16 (37.5%) 0/16 (0%) 7/19 (36.8%)
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Fig. 3 Pharmacokinetic parameters. a Plasma letrozole levels at both dose levels, comparing in each the mean plasma levels in nanograms per
milliliter on day 29 versus 1 along the 24-h course. b, c The same as in a for both active nintedanib metabolites BIBF1120-BS and BIBF1202-ZW,
respectively. N = 3 in level 1; N = 16 in level 2. Error bars: standard error
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a metastatic setting or decreasing the relapse rate of this
disease cluster in an adjuvant setting will require
time-consuming and expensive clinical trials that involve
prolonged concurrent administration of an FGFR inhibitor
plus a standard hormonal blockade. Although various
molecules with selective and non-selective activity in regu-
lating the FGFR family have been developed, data con-
cerning their use in combination with hormonal agents
are scarce [6]. A clinical trial that combined fulvestrant
with the multikinase inhibitor lucitanib was prematurely
terminated; however, the patients in that trial had been
previously exposed to fulvestrant, and toxicity limited the
administration of lucitanib at full doses [31]. Another re-
cent clinical trial that combined fulvestrant with the mul-
tikinase inhibitor dovitinib or a placebo showed promising
signs of clinical activity in a FGFR-amplified breast cancer
population [32]. However, to the best of our knowledge,
this is the first trial to demonstrate effective inhibition of
both pathways of interest (17-B-estradiol synthesis and
FGFR1 signaling).
Clinical trials with other FGFR inhibitors have re-
ported variable degrees increased FGF23 concentrations.
These increases ranged from ~ 20 to ~ 50% at the RP2Ds
for JNJ-42756493 [8] and BGJ398 [9], respectively. To
our knowledge, there is no previous evidence for FGFR1
being modulated by nintedanib, when administered at
standard doses. Here, we have provided proof for this
modulation by observing an average ~ 50% increase
FGF23 levels on day 15 versus 0 (Fig. 2a). Despite this
increase, a number of patients did not experience that
result. However, a dose-response effect was observed be-
tween nintedanib exposure and FGF23 levels (Fig. 2b).
The reason why some patients achieve greater drug ex-
posure than others with the same drug dosages needs to
be explored in large pharmacogenomic studies but is
commonly observed in phase I trials. Regardless, the
dose-response effect (Fig. 2b) supports the FGFR1 in-
hibitory properties of nintedanib. Regarding
17-B-estradiol, despite observing an increase in letrozole
AUC values and mean plasma concentrations in dose
level 2 versus level 1 (Table 3, Fig. 3a), we also observed
a greater but non-statistically significant number of pa-
tients with detectable levels of 17-B-estradiol (Fig. 2c).
Early letrozole trials reported a > 95% suppression of
aromatase activity and a general decrease in
17-B-estradiol levels [33, 34]. However, the true percent-
age of patients who achieve suppression below the LLD
in large populations is unknown, because the large letro-
zole phase III trials conducted to date have not included
that endpoint [35–38]. Two studies addressed the degree
of 17-B-estradiol suppression in response to anastrozole
(n = 191) [39], letrozole (n = 241), or exemestane (n =
228) [40] after various treatment periods (4 weeks to 6
months). In the anastrozole study, it was found that 83%
of the patients displayed plasma 17-B-estradiol concen-
trations below the LLD [39]. In the second study, 89%
and 86.9% of the patients had suppressed levels of
17-B-estradiol after treatment with letrozole and exe-
mestane, respectively [40]. An additional study random-
ized patients to 3 months of letrozole followed by 3
months of anastrozole and then compared them to pa-
tients randomized to the opposite sequence. That study
found a greater suppression of 17-B-estradiol levels
among patients who received letrozole, with only 2% of
patients being above the LLD (compared to 37% of the
patients who received anastrozole) [41]. The number of
patients with 17-B-estradiol levels above the LLD was
not significantly higher in our study; however, the lack
of testing at different time points in the other studies
[39, 40] limits our ability to conclude whether the fact
that 17-B-estradiol suppression was observed in 100% of
the patients after nintedanib cessation is significant. An
additional limitation to our study is that 17-B-estradiol
was detected with a clinical assay that was not suffi-
ciently sensitive to detect residual levels, while in letro-
zole treatment compared to the tenfold more sensitive
assay used by Dixon and colleagues [41]. Regardless, the
fact that across all the different studies, up to 15% of the
patients did not show complete 17-B-estradiol suppres-
sion, and taking into account that large numbers of
Table 3 Day 1 and day 29 pharmacokinetic parameters (letrozole and nintedanib)
LET Mean Cmax
(ng/ml)
Mean Tmax (h) Mean AUC0-last
(ng-h/ml)
NINT Mean Cmax
(ng/ml)
Mean Tmax (h) Mean AUC0-last
(ng-h/ml)
Level 1 day 1 100.2 0 2204 BS level 1 day 1 51 1.9 339
Level 1 day 29 89.4 4 2059 BS level 1 Day 29 50 1.1 519
Level 2 day 1 124.5 4 2782 BS level 2 day 1 65 2.0 599
Level 2 day 29 148.0 2 3170 BS level 2 day 29 92 2.0 941
ZW level 1 day 1 24 1.9 200
ZW level 1 day 29 28 1.1 367
ZW level 2 day 1 41 3.3 413
ZW level 2 day 29 67 3.0 824
LET letrozole, NINT nintedanib, BS BIBF1120-BS, ZW BIBF1202-ZW
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patients receive aromatase inhibitors in an adjuvant set-
ting, the insufficient suppression of 17-B-estradiol levels
might be a significant factor contributing to the
non-negligible number of metastatic relapses. Careful
monitoring of 17-B-estradiol levels should be combined
with individual pharmacogenomics data in a future pro-
spective study designed to improve the individualized
treatment of hormone receptor-positive advanced breast
cancer.
Although multikinase inhibitors are associated with
significant toxicity [42–44], nintedanib has consistently
shown long-term acceptable tolerance when adminis-
tered at 200 mg/bid [13, 14, 45, 46]. Our study included
a 28-day period for DLT assessment and that short-term
assessment period was used to determine the RP2D. Fur-
thermore, the short-term toxicities seen with nintedanib
were mild (Table 2), and allowed escalation to the cur-
rently recommended standard dose of nintedanib, des-
pite concurrent letrozole administration. However,
besides the fact that most of the toxic events were grade
1/2 (Table 2), toxicities such as diarrhea, nausea, vomit-
ing, or fatigue clearly impacted the long-term tolerability
of the treatment regimen, and due to various reasons as-
sociated with sustained, low-grade toxicity, only 6 out of
16 patients in dose level 2 completed all 6 treatment cy-
cles. Also, the previous administration chemotherapy to
1/3 of the patients enrolled in the study may have influ-
enced the long-term tolerance to the dosing regimen.
The importance of collecting and evaluating long-term
tolerability data, and considering it when designing long
treatment periods such as those in an adjuvant stage,
must be underscored. Conversely, no patient decided to
withdraw their consent and abandon our trial because of
toxicities allegedly related to letrozole, although it
should be highlighted that this trial was conducted in
patients who had been shown to tolerate letrozole. Inter-
estingly, we did not notice meaningful rates of toxicities
commonly associated with specific FGR1 inhibitors, such
as hyperphosphatemia, mucositis, and osteoarticular
toxicity [6].
Pharmacokinetic interactions may explain the
long-term toxicity observed in our study. Although nin-
tedanib pharmacokinetic parameters were assessed only
during cycle 1, the comparison made between day 29
and day 1 clearly suggested drug accumulation. Both
letrozole and nintedanib are metabolized by Cyp3A4,
and in line with our results, it appears that this inter-
action is clinically significant (Table 3; Fig. 3b, c). The
BIBF1120-BS AUC values on day 29 were almost two-
fold higher than those recorded on day 1 and were two
to threefold higher than the steady-state values reported
in phase I studies of nintedanib monotherapy [28], nicte-
danib combined with pemetrexed [27], or paclitaxel plus
carboplatin [47]. Regarding letrozole, although we
observed the same effects (an increase on day 29 versus
day 1 and in level 2 versus 1), the plasma letrozole levels
were similar to those observed in healthy subjects
treated with letrozole [48]. Those levels were also in line
(or lower) with letrozole levels previously reported in
cancer patients enrolled in monotherapy [33] and com-
bination studies [34, 49, 50]. This may explain the lack
of dropouts due to letrozole-related toxicity. Because
exemestane [51] and anastrazole [52] are also metabo-
lized by Cyp3A4, it might be difficult to avoid nintedanib
accumulation. Although other hormonal inhibitors exist,
pharmacodynamic determinations of activity for tamoxi-
fen or fulvestrant would imply serial sampling of tumor
tissue and complex quantitation procedures given their
mechanisms of action, complicating the conduction of a
phase 0 trial.
The following facts should be taken into consideration
when planning to conduct a clinical trial in an adjuvant
or metastatic setting where the patients would receive
this type of combination therapy for a prolonged period
of time: (1) we did not observe significant differences be-
tween the FGF23 and/or letrozole levels in dose levels 1
and 2, although the small number of patients in level 1
precludes concluding that FGFR1 and aromatase were
effectively modulated at a dose of 150 mg/bid; (2) our
pharmacokinetic data suggest that not all patients
achieved effective FGFR1 inhibition; however, the likeli-
hood of achieving effective inhibition is directly related
to the nintedanib AUC value; (3) a pharmacokinetic
interaction occurs between letrozole and nintedanib that
results in nintedanib accumulation in the long term; and
(4) in the long term, the combination of nintedanib plus
letrozole produces a moderate rate of non-tolerable tox-
icity. Based on these findings, we propose proceeding ac-
cording to the following algorithm: a patient should start
at 200 mg/bid of nintedanib plus 2.5 mg of letrozole.
The FGF23 level should be determined after 2 weeks
and compared with the level at baseline. If a > 25% in-
crease in FGF23 is observed, and the treatment regimen
is tolerated, the patient should continue at the same
level. If a < 25% increase in FGF23 is observed, the pa-
tient should stop taking the drug because of its uncer-
tain pharmacodynamic effect. In the first case, if
non-tolerable toxicity is observed, one dose reduction
(to 200 mg/bid of nintedanib plus 2.5 mg of letrozole)
should be attempted, and FGF23 patient’s level should
be re-determined 2 weeks later. The final decision on
whether to continue the treatment should depend on
whether an effective pharmacodynamic modulation can
still be observed.
In conclusion, our study met its primary endpoint by
showing pharmacodynamic evidence of FGFR1 modula-
tion at the RP2D and no significant impact on the abil-
ity of letrozole to suppress 17-B-estradiol activity. The
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RP2D was defined as 200 mg/bid of nintedanib com-
bined with 2.5 mg/day of letrozole. The tolerance to
this dosing regimen was acceptable in the short term,
although in the long term, the cumulative and durable
incidence of low-grade toxicities such as diarrhea and
asthenia led to patient attrition and a meaningful pa-
tient dropout rate. These toxic effects may have been
caused by a pharmacokinetic interaction between letro-
zole and nintedanib that resulted in increased plasma
concentrations of the latter drug. However, this prob-
lem can be solved by nintedanib dose reductions “on
demand,” and other methods for solving this problem
can be guided by making serial FGF23 determinations,
given the direct correlation between nintedanib expos-
ure and FGF23 levels. Data concerning the clinical effi-
cacy of a FGFR1 inhibitor used in combination with
hormonal treatment in cases of breast cancer are still
scarce. Taken together, a clinical trial testing the effi-
cacy of nintedanib plus letrozole, and restricted to
metastatic FGFR1-amplified hormone receptor-positive
breast cancer patients, would be the reasonable next
step in such clinical investigations.
Conclusion
The combination of nintedanib (200 mg/bid) plus letro-
zole (2.5 mg/d) effectively inhibited both FGFR1 and
aromatase in breast cancer patients, as evidenced by
plasma FGF23 and 17-B-estradiol levels. This combin-
ation produced a moderate rate of non-tolerable toxicity
in the long term; thus, in order to conduct a clinical trial
that includes prolonged treatment in an adjuvant or
metastatic setting, a careful toxicity assessment com-
bined with FGF23 monitoring should be incorporated
into the study protocol. Given the increased use of CDK
inhibitors in standard of care protocols and the limited
activity of selective FGFR inhibitors in FGFR1-amplified
breast cancer in basket trials, based on the safety and
pharmacodynamic data found on this study, the combin-
ation could be further evaluated in molecularly selected
patients the moment there is a compelling clinical/pre-
clinical rationale supporting a specific target niche.
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